

Compounds interfering with Embryonic Lethal Abnormal Vision (ELAV) protein–RNA complexes: an avenue for discovering new drugs

Rita Nasti[†], Daniela Rossi[†], Marialaura Amadio[‡], Alessia Pascale[‡], M. Yagiz Unver[§], Anna K.H Hirsch[§], Simona Collina^{†*}

[†] Department of Drug Science, Medicinal Chemistry Division, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy

[‡] Department of Drug Science, Pharmacological Division, University of Pavia, Via Taramelli 14, 27100 Pavia, Italy

[§] Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, NL-9747 AG Groningen, The Netherlands


*Corresponding author: Prof. Simona Collina, e-mail: simona.collina@unipv.it, phone+39 0382987379

Supporting information


Predicted binding mode of compounds.

These binding modes are the result of a docking run using the FlexX docking module with 30 poses and represent the top-scoring pose after HYDE scoring with SEESAR and careful visual inspection to exclude poses with significant inter- or intra-molecular clash terms or unfavorable conformations. The figures were generated with PoseView as implemented in the LeadIT suite.


Compounds 1–3






Compounds 9–11






Compound 13



Compounds 14–19





Compounds 20–22

